NewAmsterdam Pharma Company N.V. Amortization of Debt Issuance Costs and Discounts
NewAmsterdam Pharma Company N.V. (NAMS) reported Amortization of Debt Issuance Costs and Discounts of -$42.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfFinancingCostsAndDiscounts · last filed 2026-08-05
- NewAmsterdam Pharma Company N.V. amortization of debt issuance costs and discounts for the quarter ending 2026-06-30 was -$52.00K.
- NewAmsterdam Pharma Company N.V. amortization of debt issuance costs and discounts for the quarter ending 2026-03-31 was $10.00K.
- NewAmsterdam Pharma Company N.V. amortization of debt issuance costs and discounts for the quarter ending 2025-12-31 was -$24.00K.
- NewAmsterdam Pharma Company N.V. amortization of debt issuance costs and discounts for the quarter ending 2025-09-30 was -$396.00K.
- NewAmsterdam Pharma Company N.V. amortization of debt issuance costs and discounts for fiscal 2025 was -$1.41M.
- NewAmsterdam Pharma Company N.V. amortization of debt issuance costs and discounts for fiscal 2024 was -$227.00K.
| Period end | Amortization of Debt Issuance Costs and Discounts 3 month | Amortization of Debt Issuance Costs and Discounts 6 month | Amortization of Debt Issuance Costs and Discounts 9 month | Amortization of Debt Issuance Costs and Discounts 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$52.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$42.00K 10-Q · filed 2026-08-05 | -$66.00K derived: sum of 3 quarters · filed 2026-08-05 | -$462.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $10.00K 10-Q · filed 2026-05-07 | -$14.00K derived: sum of 2 quarters · filed 2026-05-07 | -$410.00K derived: sum of 3 quarters · filed 2026-05-07 | -$882.00K derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-18 | -$420.00K derived: sum of 2 quarters · filed 2026-02-18 | -$892.00K derived: sum of 3 quarters · filed 2026-08-05 | -$1.41M 10-K · filed 2026-02-18 |
| 2025-09-30 | -$396.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$868.00K derived: sum of 2 quarters · filed 2026-08-05 | -$1.38M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | -$472.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$985.00K 10-Q · filed 2026-08-05 | ||
| 2025-03-31 | -$513.00K 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | -$227.00K 10-K · filed 2026-02-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |